<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61371">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02306980</url>
  </required_header>
  <id_info>
    <org_study_id>531791</org_study_id>
    <nct_id>NCT02306980</nct_id>
  </id_info>
  <brief_title>Oral Administration of Colostrum to Premature Babies: Impact on the Oral Microbiota</brief_title>
  <official_title>Oral Administration of Colostrum to Premature Babies: Impact on the Oral Microbiota</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oropharyngeal administration of mother's colostrum to premature infants has been proposed as
      a stimulus to the oropharyngeal lymphatic tissues to decrease the incidence of pneumonia and
      sepsis, particularly in intubated babies. We propose to study the impact of this
      intervention on the composition of the oral microbiota.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oral microbiota</measure>
    <time_frame>96 hours</time_frame>
    <description>Three samples: enrollment, 48 hours, 96 hours</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Changes in the Oral Microbiota</condition>
  <arm_group>
    <arm_group_label>Colostrum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colostrum administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Routine care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Colostrum</intervention_name>
    <description>Mother's own colostrum (0.2 ml) will be administered into the mouth of the infant every 2 hours for 48 hours.</description>
    <arm_group_label>Colostrum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  premature infant with birth weight &lt; 1500

          -  intubated in the first 48 hours of life

          -  available maternal colostrum

        Exclusion Criteria:

          -  lethal condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark A Underwood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark A Underwood, MD</last_name>
    <phone>916-734-8672</phone>
    <email>mark.underwood@ucdmc.ucdavis.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristin Sohn, MD</last_name>
    <phone>916-734-2428</phone>
    <email>kristin.sohn@ucdmc.ucdavis.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC Davis Children's Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mark A Underwood, MD</last_name>
      <phone>916-734-8672</phone>
      <email>mark.underwood@ucdmc.ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristin Sohn, MD</last_name>
      <phone>916-734-2428</phone>
      <email>kristin.sohn@ucdmc.udcavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mark A Underwood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>December 1, 2014</lastchanged_date>
  <firstreceived_date>December 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
